Canada approves first bivalent Covid-19 booster for children aged 5-11

Last Updated on December 10, 2022 by IANS

Ottawa, Dec 10 (IANS) Health Canada has authorised the Pfizer-BioNTech Comirnaty Omicron BA.4/BA.5 bivalent-adapted booster for use in children aged between 5 to 11 years.

This is the first bivalent Covid-19 booster authorised for use in this age group that targets the original Covid-19 strain and the Omicron BA.4/BA.5 subvariants, Health Canada said in a statement on Friday.

According to the statement, Health Canada previously authorised this bivalent booster for use in individuals aged 12 years and older on October 7, 2022. While the formulation for children aged between 5 to 11 years is the same, the dose is one-third of that authorised for individuals aged 12 years and older.

The statement added that after a thorough and independent scientific review of the evidence, Health Canada has determined that the Pfizer-BioNTech Comirnaty Omicron BA.4/BA.5 bivalent-adapted booster vaccine for children aged between 5 to 11 years is safe and effective and that its benefits outweigh any potential risks, Xinhua news agency reported.

Vaccination continues to be one of the most effective tools to protect families and communities against Covid-19, Health Canada said.

–IANS

int/khz/

Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it's social media channels. Read our Full Disclaimer Here for further information.